Candel Therapeutics, INC Schedule 13G passive stakes

RTW Investments, LP and Roderick Wong, M.D. have jointly filed a Schedule 13G, reporting beneficial ownership of 8.8% of Candel Therapeutics, Inc. common stock as of March 31, 2026.

BlackRock Inc. has reported a 4.2% beneficial ownership in Candel Therapeutics Inc. as of March 31, 2026, holding over 3 million shares.

BlackRock, Inc. has reported a 5.2% beneficial ownership stake in Candel Therapeutics Inc. common stock as of December 31, 2025.

Acorn Bioventures, L.P., along with its affiliates and manager Anders Hove, has disclosed a collective passive beneficial ownership of 5.2% of Candel Therapeutics, Inc.'s common stock.

Baker Bros. Advisors LP and its affiliates have filed an Amendment No. 1 to their Schedule 13G, disclosing a 4.99% beneficial ownership stake in Candel Therapeutics, Inc. as of March 31, 2025.

Northpond Ventures and its affiliated entities have filed an amended Schedule 13G, indicating they no longer beneficially own any shares of Candel Therapeutics, Inc. common stock as of December 31, 2024.

Baker Bros. Advisors LP and its affiliates have reported a 6.8% beneficial ownership stake in Candel Therapeutics, Inc., holding 2,981,983 shares of common stock as of December 31, 2024.

CVI Investments, Inc. and its investment manager, Heights Capital Management, Inc., have filed an amended Schedule 13G indicating they no longer beneficially own any shares of Candel Therapeutics, Inc. as of December 31, 2024.

FMR LLC and Abigail P. Johnson have filed an amended Schedule 13G, revealing a significant 15.0% beneficial ownership stake in Candel Therapeutics Inc. as of January 31, 2025.

FMR LLC and its Chairman and CEO, Abigail P. Johnson, have disclosed a beneficial ownership of 9.3% in Candel Therapeutics Inc.'s common stock as of December 31, 2024.